Emerging Role of Engineered Exosomes in Nonalcoholic Fatty Liver Disease

Overview

Journal World J Hepatol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2023 Apr 10

PMID 37034232

Authors

Jian Ding

Chen Xu

Ming Xu

Xiao-Yue He

Wei-Na Li

Fei He

Affiliations

Soon will be listed here.

Abstract

Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease worldwide. NAFLD comprises a continuum of liver abnormalities from nonalcoholic fatty liver to nonalcoholic steatohepatitis, and can even lead to cirrhosis and liver cancer. However, a well-established treatment for NAFLD has yet to be identified. Exosomes have become an ideal drug delivery tool because of their high transmissibility, low immunogenicity, easy accessibility and targeting. Exosomes with specific modifications, known as engineered exosomes, have the potential to treat a variety of diseases. Here, we review the treatment of NAFLD with engineered exosomes and the potential use of exosomes as biomarkers and therapeutic targets for NAFLD.

Citing Articles

Priming mesenchymal stem cells to develop "super stem cells".

Haider K World J Stem Cells. 2024; 16(6):623-640.

PMID: 38948094 PMC: 11212549. DOI: 10.4252/wjsc.v16.i6.623.

References

Barile L, Vassalli G . Exosomes: Therapy delivery tools and biomarkers of diseases. Pharmacol Ther. 2017; 174:63-78. DOI: 10.1016/j.pharmthera.2017.02.020. View

Schuster S, Cabrera D, Arrese M, Feldstein A . Triggering and resolution of inflammation in NASH. Nat Rev Gastroenterol Hepatol. 2018; 15(6):349-364. DOI: 10.1038/s41575-018-0009-6. View

Abdullah M, Nakamura T, Ferdous T, Gao Y, Chen Y, Zou K . Cholesterol Regulates Exosome Release in Cultured Astrocytes. Front Immunol. 2021; 12:722581. PMC: 8551362. DOI: 10.3389/fimmu.2021.722581. View

Xia Y, Rao L, Yao H, Wang Z, Ning P, Chen X . Engineering Macrophages for Cancer Immunotherapy and Drug Delivery. Adv Mater. 2020; 32(40):e2002054. DOI: 10.1002/adma.202002054. View

Meng W, Hao Y, He C, Li L, Zhu G . Exosome-orchestrated hypoxic tumor microenvironment. Mol Cancer. 2019; 18(1):57. PMC: 6441221. DOI: 10.1186/s12943-019-0982-6. View

Crewe C, Funcke J, Li S, Joffin N, Gliniak C, Ghaben A . Extracellular vesicle-based interorgan transport of mitochondria from energetically stressed adipocytes. Cell Metab. 2021; 33(9):1853-1868.e11. PMC: 8429176. DOI: 10.1016/j.cmet.2021.08.002. View

Watt M, Miotto P, De Nardo W, Montgomery M . The Liver as an Endocrine Organ-Linking NAFLD and Insulin Resistance. Endocr Rev. 2019; 40(5):1367-1393. DOI: 10.1210/er.2019-00034. View

Dabravolski S, Bezsonov E, Orekhov A . The role of mitochondria dysfunction and hepatic senescence in NAFLD development and progression. Biomed Pharmacother. 2021; 142:112041. DOI: 10.1016/j.biopha.2021.112041. View

Paradies G, Paradies V, Ruggiero F, Petrosillo G . Oxidative stress, cardiolipin and mitochondrial dysfunction in nonalcoholic fatty liver disease. World J Gastroenterol. 2014; 20(39):14205-18. PMC: 4202349. DOI: 10.3748/wjg.v20.i39.14205. View

10.

Wang N, Li X, Zhong Z, Qiu Y, Liu S, Wu H . 3D hESC exosomes enriched with miR-6766-3p ameliorates liver fibrosis by attenuating activated stellate cells through targeting the TGFβRII-SMADS pathway. J Nanobiotechnology. 2021; 19(1):437. PMC: 8686281. DOI: 10.1186/s12951-021-01138-2. View

11.

Hyung S, Jeong J, Shin K, Kim J, Yim J, Yu C . Exosomes derived from chemically induced human hepatic progenitors inhibit oxidative stress induced cell death. Biotechnol Bioeng. 2020; 117(9):2658-2667. PMC: 7496643. DOI: 10.1002/bit.27447. View

12.

Li Y, Luan Y, Li J, Song H, Li Y, Qi H . Exosomal miR-199a-5p promotes hepatic lipid accumulation by modulating MST1 expression and fatty acid metabolism. Hepatol Int. 2020; 14(6):1057-1074. DOI: 10.1007/s12072-020-10096-0. View

13.

Wan T, Zhong J, Pan Q, Zhou T, Ping Y, Liu X . Exosome-mediated delivery of Cas9 ribonucleoprotein complexes for tissue-specific gene therapy of liver diseases. Sci Adv. 2022; 8(37):eabp9435. PMC: 9473578. DOI: 10.1126/sciadv.abp9435. View

14.

Gao H, Jin Z, Bandyopadhyay G, Cunha E Rocha K, Liu X, Zhao H . MiR-690 treatment causes decreased fibrosis and steatosis and restores specific Kupffer cell functions in NASH. Cell Metab. 2022; 34(7):978-990.e4. PMC: 9262870. DOI: 10.1016/j.cmet.2022.05.008. View

15.

Luo X, Xu Z, Wu J, Luo S, Xu M . Hepatocyte-derived exosomal miR-27a activateshepatic stellate cells through the inhibitionof PINK1-mediated mitophagy in MAFLD. Mol Ther Nucleic Acids. 2021; 26:1241-1254. PMC: 8607138. DOI: 10.1016/j.omtn.2021.10.022. View

16.

Zhang G, Huang X, Xiu H, Sun Y, Chen J, Cheng G . Extracellular vesicles: Natural liver-accumulating drug delivery vehicles for the treatment of liver diseases. J Extracell Vesicles. 2020; 10(2):e12030. PMC: 7726052. DOI: 10.1002/jev2.12030. View

17.

Zhou X, Li Z, Qi M, Zhao P, Duan Y, Yang G . Brown adipose tissue-derived exosomes mitigate the metabolic syndrome in high fat diet mice. Theranostics. 2020; 10(18):8197-8210. PMC: 7381731. DOI: 10.7150/thno.43968. View

18.

Goossens G . The Metabolic Phenotype in Obesity: Fat Mass, Body Fat Distribution, and Adipose Tissue Function. Obes Facts. 2017; 10(3):207-215. PMC: 5644968. DOI: 10.1159/000471488. View

19.

Younossi Z, Anstee Q, Marietti M, Hardy T, Henry L, Eslam M . Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2017; 15(1):11-20. DOI: 10.1038/nrgastro.2017.109. View

20.

Tian X, Wang C, Jin X, Li M, Wang F, Huang W . Acidic Microenvironment Up-Regulates Exosomal miR-21 and miR-10b in Early-Stage Hepatocellular Carcinoma to Promote Cancer Cell Proliferation and Metastasis. Theranostics. 2019; 9(7):1965-1979. PMC: 6485281. DOI: 10.7150/thno.30958. View